aspirin has been researched along with osimertinib in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Han, R; Hao, S; He, Y; Hu, C; Li, L; Lin, C; Lu, C; Wang, Y; Zhang, C | 1 |
Fang, B; He, Y; Heymach, JV; Hong, L; Hubert, SM; Jack Lee, J; Le, X; Lewis, J; Liu, X; Nilsson, M; Rinsurongkawong, W; Roth, J; Spelman, A; Swisher, S; Wu, S; Zhang, J | 1 |
2 other study(ies) available for aspirin and osimertinib
Article | Year |
---|---|
Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Animals; Apoptosis; Aspirin; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forkhead Box Protein O3; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mutation; Proto-Oncogene Proteins c-akt; Signal Transduction; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2020 |
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.
Topics: Acrylamides; Aniline Compounds; Aspirin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Retrospective Studies | 2020 |